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Abstract
Background: Cigarette smoking is the primary cause of bronchogenic carcinoma (BC), yet only 10–15%
of heavy smokers develop BC and it is likely that this variation in risk is, in part, genetically determined.
We previously reported a set of antioxidant genes for which transcript abundance was lower in normal
bronchial epithelial cells (NBEC) of BC individuals compared to non-BC individuals. In unpublished studies
of the same NBEC samples, transcript abundance values for several DNA repair genes were correlated
with these antioxidant genes. From these data, we hypothesized that antioxidant and DNA repair genes
are co-regulated by one or more transcription factors and that inter-individual variation in expression and/
or function of one or more of these transcription factors is responsible for inter-individual variation in risk
for BC.
Methods: The putative transcription factor recognition sites common to six of the antioxidant genes
were identified through in silico DNA sequence analysis. The transcript abundance values of these
transcription factors (n = 6) and an expanded group of antioxidant and DNA repair genes (n = 16) were
measured simultaneously by quantitative PCR in NBEC of 24 non-BC and 25 BC individuals.
Results: CEBPG transcription factor was significantly (p < 0.01) correlated with eight of the antioxidant
or DNA repair genes in non-BC individuals but not in BC individuals. In BC individuals the correlation with
CEBPG was significantly (p < 0.01) lower than that of non-BC individuals for four of the genes (XRCC1,
ERCC5, GSTP1, and SOD1) and the difference was nearly significant for GPX1. The only other
transcription factor correlated with any of these five target genes in non-BC individuals was E2F1. E2F1
was correlated with GSTP1 among non-BC individuals, but in contrast to CEBPG, there was no significant
difference in this correlation in non-BC individuals compared to BC individuals.
Conclusion: We conclude that CEBPG is the transcription factor primarily responsible for regulating
transcription of key antioxidant and DNA repair genes in non-BC individuals. Further, we conclude that
the heavy smokers selected for development of BC are those who have sub-optimal regulation of
antioxidant and DNA repair genes by CEBPG.
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BC is currently the leading cause of cancer-related death in
the United States, causing 28% of all cancer deaths [1].
Although cigarette smoking is the primary risk factor, only
10–15% of heavy smokers (greater than 20 pack years)
develop BC [1-3]. Antioxidant and DNA repair enzymes
that provide protection from the effects of cigarette smoke
are expressed in the progenitor cells for BC, normal bron-
chial epithelial cells (NBEC) [1]. Inherited inter-individ-
ual variation in the function of these genes plays a role in
determining risk for BC [4-6]. Antioxidant enzymes pro-
tect NBEC from reactive oxygen species produced by inter-
action with and metabolism of xenobiotics such as
pollution and cigarette smoke [4-7] as well as those pro-
duced by normal cellular metabolism. Reactive oxygen
species cause many damaging reactions including dena-
turation of proteins, cross-linking of lipids and proteins
and modification of nucleic acid bases, which can lead to
cancer [7]. DNA repair enzymes repair the frequent dam-
age to DNA caused by oxidant stress as well as other
stresses, including bulky adducts derived from carcino-
gens in cigarette smoke [8].
We previously reported that an interactive transcript
abundance index comprising antioxidant genes was lower
in NBEC of BC individuals compared to non-BC individ-
uals, suggesting that BC individuals are selected on the
basis of poor antioxidant protection [9]. In that study,
there was a tendency towards correlation in transcript
abundance between several pairs of antioxidant or DNA
repair genes in non-BC individuals, but not in BC individ-
uals. Gene pairs included in that observation were GSTP1/
GPX1, CAT/GPX3, and GPX3/SOD1.
Correlation is one typical characteristic of co-regulated
genes. Another is shared transcription factor recognition
sites in the regulatory regions of those genes [10]. Based
on the above findings, it was hypothesized first, that there
is inter-individual variation in regulation of key antioxi-
dant and DNA repair genes by one or more transcription
factors and second, that individuals with sub-optimal reg-
ulation are selected for development of BC if they smoke
cigarettes. To test these hypotheses, transcription factor
recognition sites common to the regulatory regions of the
above correlated gene pairs were identified through in sil-
ico DNA sequence analysis, and their transcript abun-
dance measured simultaneously with an expanded group
of ten antioxidant and six DNA repair genes.
Methods
NBEC sample procurement
Brush biopsy samples of normal bronchial epithelium
were obtained for research studies at the time of diagnos-
tic bronchoscopy according to previously described meth-
ods [9,11]. Normal bronchial epithelium in the lung not
involved with cancer was brushed prior to biopsy of the
suspected cancerous area. Samples were collected in a
manner satisfying all requirements of the Institutional
Review Board for the Medical University of Ohio. Each BC
diagnosis and subtype identification was determined by
histopathological examination in the Department of
Pathology at the Medical University of Ohio. NBEC sam-
ples from a total of 49 individuals, including 24 non-BC
individuals and 25 BC individuals, were evaluated in this
study. The biographical characteristics of these individuals
are presented in Table 1.
Transcript abundance measurement
Total RNA samples extracted from NBEC were reverse
transcribed using M-MLV reverse transcriptase and oligo
dT primers as previously described [9,11]. Standardized
RT (StaRT)-PCR was used for transcript abundance meas-
urement in these studies. With StaRT-PCR, an internal
standard for each gene within a standardized mixture of
internal standards (SMIS) is included in each PCR reac-
tion. After amplification, products were electrophoresed
on an Agilent 2100 Bioanalyzer using DNA Chips with
DNA 1000 Kit reagents for visualization according to the
manufacturer's protocol (Agilent Technologies Deutsch-
land GmbH, Waldbronn, Germany).
The StaRT-PCR technology is licensed to Gene Express,
Inc. (Toledo, OH). Many of the reagents are available
commercially and were obtained through Gene Express,
Inc. for this study. StaRT-PCR reagents for each of the
measured genes that were not commercially available,
including primers and SMIS, were prepared according to
previously described methods [11,12]. Sequence informa-
tion for the primers is provided in Table 2.
Including an internal standard within a SMIS in each
measurement controls for all known sources of variation
during PCR, including inhibitors in samples, and gener-
ates virtually-multiplexed transcript abundance data that
are directly comparable across multiple experiments and
institutions [13]. The performance characteristics of
StaRT-PCR are superior to other forms of commercially
available quantitative PCR technology in the areas critical
to this study. With respect to these studies, the key prop-
erty of a quantitative PCR method is not whether the PCR
products are measured kinetically or at endpoint, but
rather whether there are internal standards in each meas-
urement or not. The overall performance characteristics of
StaRT-PCR, including extensive validation of the method
in independent laboratories have been presented in sev-
eral recent articles and chapters [13-15]. With respect to
the genes measured in this study, for each gene the StaRT-
PCR reagents had lower detection threshold of less than
10 molecules, linear dynamic range of more than six
orders of magnitude (less than 10 to over 107 molecules),Page 2 of 14
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presence of an internal standard controls for inter-sample
variation in presence of PCR inhibitors (which often are
gene-specific) and ensures no false negatives (if the PCR
fails the internal standard PCR product is not observed
and there are no data to report). False positives are elimi-
Table 1: Demographic data of patients from whom the NBEC samples were obtained.
Subject # Group Age Gender Histology Smoking Hx1 Ethnicity
63 NBCI2 77 M 75 W3
64 NBCI 47 F 45 W
136 NBCI 38 M 25 A.A.4
139 NBCI 44 F 17.5 W
150 NBCI 70 F 45 W
156 NBCI 46 F NS5 A.A.
157 NBCI 60 M >100 W
194 NBCI 57 M 3 W
210 NBCI 40 M 34 W
257 NBCI 69 F 20 W
261 NBCI 73 F NS W
282 NBCI 83 F 60 W
285 NBCI 69 F NS W
296 NBCI 43 F 20 W
305 NBCI 50 F 40 W
315 NBCI 64 M N/A6 W
330 NBCI 39 M NS W
331 NBCI N/A N/A N/A N/A
334 NBCI 51 M >50 W
336 NBCI 31 F NS W
337 NBCI 32 M 22 N/A
339 NBCI 59 M 50 W
361 NBCI 73 F NS H7
363 NBCI 50 M 20 A.A.
34 BCI8 80 M NSCLC9 40 W
71 BCI 63 M NSCLC 100 W
85 BCI 73 F SQ10 >100 W
88 BCI 85 M SQ 75 W
99 BCI 63 M NSCLC 45 W
118 BCI 72 M SQ 30 W
146 BCI 64 F SCLC11 45 W
147 BCI 76 M SCLC 75 W
158 BCI 88 M SCLC 115.5 W
167 BCI 60 F NSCLC 50 W
171 BCI 67 M SCLC 100 W
191 BCI 75 M SQ 54 W
211 BCI 71 M SQ 50 W
212 BCI 65 M SQ 67.5 W
247 BCI 75 F SQ 50 W
255 BCI 60 F NSCLC 30 W
259 BCI 68 M CS12 137.5 W
271 BCI 58 M AC13 94.5 W
287 BCI 65 F NSCLC 50 W
300 BCI 56 M SQ 34 W
306 BCI 46 M SQ 30 W
314 BCI 69 F BC14 NS W
329 BCI 76 F PD15 >37.5 W
335 BCI 75 M SCLC 58 A.A.
B3 BCI 63 M SQ 60 W
1Pack years; 2Non-bronchogenic carcinoma individual; 3White; 4African-American; 5Non-smoker; 6Not available; 7Hispanic; 8Bronchogenic 
carcinoma individual; 9Non-small cell lung cancer; 10Squamous carcinoma; 11Small cell lung cancer; 12Carcinoma-in-situ; 
13Adenocarcinoma;14Bronchogenic Cancer, histology not specified; 15Poorly differentiated carcinoma.Page 3 of 14
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standard preparation (CT) [15].
Gene Accession # Primer Sequence Position Product
ACTB X00351 Forward 5' ATC CTC ACC CTG AAG TAC CC 3' 231
Reverse 5' CCA TCT CTT GCT CGA AGT CC 3' 704 493 bp
CT 5' CCA TCT CTT GCT CGA AGT CCG CCA GCC AGG TCC AGA CGC A 
3'
568 377 bp
CAT X04076 Forward 5' CCA GAA GAA AGC GGT CAA GA 3' 1492
Reverse 5' AAC CTT CAT TTT CCC CTG GG 3' 1822 350 bp
CT 5' AAC CTT CAT TTT CCC CTG GGC CAG TGA TGA GCG GGT TAC A 
3'
1699 247 bp
CEBPB NM_005194 Forward 5' TGT CCA AAC CAA CCG CAC AT 3' 1412
Reverse 5' AGC AAC AAG CCC GTA GGA AC 3' 1657 265 bp
CT 5' AGC AAC AAG CCC GTA GGA ACA CGC GTT CAG CCA TGT TTA A 
3'
1571 199 bp
CEBPG U20240 Forward 5' CGG TTG AAA AGC AAG CAG AAA GCA 3' 488
Reverse 5' GAT CCC AGA AAA TAG CCT CCA ATG 3' 814 350 bp
CT 5' GAT CCC AGA AAA TAG CCT CCA ATG AAC ATT CAA GCC ACA 
AGC TC 3'
726 282 bp
E2F1 M96577 Forward 5' TGA TAC CCC AAC TCC CTC TA 3' 2076
Reverse 5' AAA GCA GGA GGG AAC AGA GC 3' 2452 396 bp
CT 5' AAA GCA GGA GGG AAC AGA GCA CTG CAG GGA CCA CAG G 3' 2363 327 bp
E2F3 Y10479 Forward 5' TGA AAG CCC CTC CAG AAA CAA G 3' 1019
Reverse 5' GCA GCA GGG GAG GCA GTA AGT T 3' 1336 339 bp
CT 5' GCA GCA GGG GAG GCA GTA AGT TGG GGA GGC CAG AGG AGA 
AAG GT 3'
1253 278 bp
E2F6 AF059292 Forward 5' GGG CCT GCT GCC ATC AAA AAT A 3' 99
Reverse 5' CCG CTT TCG GAC TCC CAG TTT 3' 283 205 bp
CT 5' CCG CTT TCG GAC TCC CAG TTA GCG ATA CAT CAA AAC GAG G 
3'
184 125 bp
ERCC1 M13194 Forward 5' CTG GAG CCC CGA GGA AGC 3' 739
Reverse 5' CAC TGG GGG TTT CCT TTG 3' 1049 328 bp
CT 5' CAC TGG GGG TTT CCT TGG AAG GCC AGA TCT TCT CTT 3 928 240 bp
ERCC2 X52221 Forward 5' GGC CTT CTT CAC CAG CTA C 3' 1608
Reverse 5' GTA GTC CGT CTT GCC CCT G 3' 2004 415 bp
CT 5' GTA GTC CGT CTT GCC CCT GTG GAA CTG GTC CCG CAG GT 3' 2597 346 bp
ERCC4 U64315 Forward 5' AGT GCA TCT CCA TGT CCC GCT ACT A 3' 2213
Reverse 5' CGA TGT TCT TAA CGT GGT GCA TCA A 3' 2578 390 bp
CT 5' CGA TGT TCT TAA CGT GGT GCA TCA ACA GGC TGT GGC TTG 
CTT TGT 3'
2433 265 bp
ERCC5 D16305 Forward 5' AAG GAA AGA GAA AGA AGC AGC AGC CA 3' 3087
Reverse 5' CAA ACA CAG ATC TGG CGG TCA CGA GG 3' 3501 440 bp
CT 5' CAA ACA CAG ATC TGG CGG TCA CGA GGA GCT TCC TTC ACT 
GAG TTC TGC GAA T 3'
3401 366 bp
EVI1 NM_005241 Forward 5' CGC CGG ATA TCC ACG AAG A 3' 302
Reverse 5' ATG CTG AGA GCG AAT GTG C 3' 711 428 bp
CT 5' ATG CTG AGA GCG AAT GTG CTT AAA TGC CTT GGG ACA CT 3' 587 323 bp
GPX1 Y00433 Forward 5' CCT GGT GGT GCT CGG CTT CC 3' 522
Reverse 5' CAA TGG TCT GGA AGC GGC GG 3' 852 350 bp
CT 5' CAA TGG TCT GGA AGC GGC GGA CCG GAG ACC AGG TGA TGA 
G 3'
757 279 bp
GPX3 D16360 Forward 5' GCA GAG CCG GGG ACA AGA GAA 3' 113
Reverse 5' CTG CTC TTT CTC TCC ATT GAC 3' 471 379 bp
CT 5' CTG CTC TTT CTC TCC ATT GAC GCT CTT CCT GTA GTG CAT 
TCA 3'
298 227 bp
GSTM1,2,4,5 J03817 Forward 5' GGG ACG CTC CTG ATT ATG AC 3' 122
Reverse 5' GCA AAC CAT GGC CGC TTC CC 3' 442 340 bp
CT 5' GCA AAC CAT GGC CGC TTC CCT TCT CCA AAA TGT CCA CAC G 
3'
301 219 bp
GSTM3 J05459 Forward 5' GTG CGA GTC GTC TAT GGT TC 3' 23
Reverse 5' AGT TGT GTG CGG AAA TCC AT 3' 342 339 bp
CT 5' AGT TGT GTG CGG AAA TCC ATT GCT CTG GGT GAT CTT GTT C 
3'
230 247 bp
GSTP1 X08058 Forward 5' TCC GCT GCA AAT ACA TCT CC 3' 305Page 4 of 14
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CT 5' TGT TTC CCG TTG CCA TTG ATT AGG ACC TCA TGG ATC AGC A 
3'
485 220 bp
GSTT1 X79389 Forward 5' GCT CTA CCT GGA CCT GCT GT 3' 12
Reverse 5' GGA ACA CAG GGA ACA TCA CC 3' 351 359 bp
CT 5' GGA ACA CAG GGA ACA TCA CCT AGA GCA GGA TGG CCA CAC T 
3'
199 227 bp
GSTZ1 U86529 Forward 5' TCA CCC CCT ACC CTA CCA TCA GC 3' 806
Reverse 5' ATT TCA GCG CGG GCA TTC TTT 3' 1267 482 bp
CT 5' ATT TCA GCG CGG GCA TTC TTT CCG CAT TCT CAT CTC AGC 
CTC AC 3'
1161 399 bp
mGST1 J03746 Forward 5' GTC GGA GCA CGG ATC TAC CAC A 3' 404
Reverse 5' TTC CTC TGC TCC CCT CCT ACC TA 3' 623 242 bp
CT 5' TTC CTC TGC TCC CCT CCT ACC TAT TTT CAG CAA CCT GTA 
AGC C 3'
505 144 bp
SOD1 X02317 Forward 5' TGA AGG TGT GGG GAA GCA TTA 3' 153
Reverse 5' TTA CAC CAC AAG CCA AAC GAC 3' 492 360 bp
CT 5' TTA CAC CAC AAG CCA AAC GAC TGA TGC AAT GGT CTC CTG 
AGA 3'
384 273 bp
XPA D14533 Forward 5' CTC GGC GAC GGC GGC TGC GGC TAC TGG AG 3' 178
Reverse 5' TGT CGG ACT TCC TTT GCT TCT TCT AAT GC 3' 629 480 bp
CT 5' TGT CGG ACT TCC TTT GCT TCT TCT AAT GCT CTT TTT TCT AAA 
TCA CAG TCT 3'
487 360 bp
XRCC1 M36089 Forward 5' CCC CTG AAG AGA CCA AAG CA 3' 1906
Reverse 5' CCA TTG AAG GCT GTG ACG TA 3' 2241 355 bp
CT 5' CCA TTG AAG GCT GTG ACG TAT CAG GGA CTG GCA GAT G 3' 2142 276 bp
Table 2: Sequence for each primer used for StaRT-PCR virtually-multiplexed transcript abundance measurement or for internal 
standard preparation (CT) [15]. (Continued)nated through use of a control PCR reaction with no
cDNA in it.
Statistical analysis
More than 6,000 transcript abundance measurements
were conducted in multiple experiments over two years to
assess the six transcription factors and sixteen antioxidant
and DNA repair genes in NBEC samples from 49 individ-
uals (24 non-BC individuals and 25 BC individuals).
Correlation of each of the six transcription factors with
each of the antioxidant or DNA repair genes was deter-
mined by Pearson's correlation following logarithmic
transformation. The transformation was necessary due to
the wide biological variation in expression of each gene
among the individuals. Significance level was defined as p
< 0.01 following Bonferroni adjustment for multiple com-
parison, specifically comparison of each of six transcrip-
tion factors to each of the antioxidant or DNA repair
genes. Comparison for significant differences between
pairs of correlation coefficients was done by Fisher's Z-
transformation test [16].
Analysis of the relationship between virtually-multiplexed
transcript abundance data for each gene with age was
assessed by Pearson's correlation, with gender by t-test,
and with smoking history by ANOVA followed by Dun-
can's test.
Transcription factor recognition site analysis
The El Dorado (Build 35) program from the Genomatix
software package was used to locate the correlated genes
within the genome and define 1101 base pairs of the pro-
moter regions (1000 base pairs upstream of and 100 base
pairs into the transcription start site) for each gene (Geno-
matix Software GmbH, Munich, Germany, [17]). The
1101 base pair sequences obtained from the El Dorado
program then were used as the target sequences for puta-
tive transcription factor recognition site identification
using the MatInspector Version 4.2 program, which
yielded sites for 11 transcription factors (Genomatix Soft-
ware GmbH, Munich, Germany, [17]). The parameters
used were the standard (0.75) core similarity and the opti-
mized matrix similarity [18]. StaRT-PCR reagents were
optimized for ten of these transcription factors, including
CEBPB, CEBPE, CEBPG, E2F1, E2F3, E2F4, E2F5, E2F6,
EVI1, and PAX5. Four transcription factors were expressed
at low and invariant levels among multiple NBEC samples
and were therefore excluded from the study. The remain-
ing six, CEBPB, CEBPG, E2F1, E2F3, E2F6, and EVI, were
evaluated for correlation with an expanded group of ten
antioxidant and six DNA repair genes.
Results
Virtually-multiplexed transcript abundance data were
obtained for each gene in each of the 49 samples, except
for E2F1 measurement in sample 147 (Table 3). A gene-Page 5 of 14
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SUBJECT # GROUP CEBPB CEBPG E2F1 E2F3 E2F6 EVI1 CAT ERCC1 ERCC2 ERCC4 ERCC5
63 NBCI 7.2E+03 6.4E+02 2.7E+02 1.9E+02 3.4E+02 6.1E+01 2.0E+04 1.1E+05 3.8E+03 1.1E+02 4.3E+04
64 NBCI 7.9E+03 1.7E+03 2.0E+03 2.0E+01 1.7E+02 2.5E+01 2.5E+04 3.0E+05 3.4E+03 8.1E+01 2.0E+05
136 NBCI 6.2E+03 2.1E+02 7.0E+02 1.0E-02 5.0E+01 6.0E+01 2.9E+03 7.4E+03 5.9E+02 5.6E+01 1.9E+04
139 NBCI 4.5E+03 3.4E+03 2.3E+04 5.6E+02 1.0E+03 1.0E+03 6.1E+05 1.2E+06 2.2E+04 3.9E+03 4.6E+05
150 NBCI 8.5E+03 7.4E+02 1.6E+02 1.1E+02 4.1E+01 3.2E+02 3.5E+04 1.7E+05 5.7E+03 6.9E+02 7.2E+04
156 NBCI 2.1E+04 1.2E+03 7.5E+02 ND1 ND 1.4E+02 1.5E+04 1.8E+05 2.0E+03 2.9E+02 3.0E+04
157 NBCI 2.3E+04 4.1E+03 3.1E+03 2.1E+02 6.1E+02 1.4E+02 3.5E+05 5.6E+05 8.4E+03 1.6E+03 2.1E+05
194 NBCI 6.5E+03 2.1E+03 2.9E+02 2.6E+02 8.5E+02 4.7E+02 4.5E+04 6.1E+05 4.7E+03 4.4E+02 8.9E+04
210 NBCI 1.0E+04 2.1E+03 7.6E+02 4.0E+02 6.1E+02 3.6E+02 7.6E+04 7.6E+04 3.4E+03 7.7E+02 7.2E+04
257 NBCI 1.1E+04 1.8E+03 2.7E+02 8.9E+02 1.7E+03 9.7E+02 1.0E+05 2.6E+05 1.6E+03 7.6E+02 7.4E+04
261 NBCI 7.6E+03 1.3E+03 2.5E+02 1.7E+02 1.6E+02 9.4E+01 4.4E+04 2.7E+05 5.1E+03 4.6E+02 1.3E+05
282 NBCI 6.4E+03 1.2E+03 5.4E+02 4.1E+01 2.9E+01 1.2E+02 4.1E+04 1.0E+05 6.0E+03 8.1E+02 4.0E+04
285 NBCI 2.6E+03 4.4E+02 2.5E+03 1.1E+03 ND 1.2E+02 3.7E+04 9.1E+04 1.6E+03 7.7E+03 1.6E+04
296 NBCI 1.9E+04 1.0E+03 1.0E+03 ND 2.8E+01 ND 6.9E+04 2.5E+05 3.6E+03 1.7E+02 7.1E+04
305 NBCI 1.8E+03 9.1E+01 6.1E+02 ND 8.7E+01 2.6E+02 2.0E+04 4.9E+04 4.3E+02 2.8E+02 1.3E+04
315 NBCI 3.5E+03 1.3E+03 1.2E+03 2.0E+02 7.5E+01 6.1E+02 4.7E+04 2.1E+05 2.7E+03 2.4E+03 6.2E+04
330 NBCI 2.7E+03 2.4E+02 4.0E+02 1.1E+02 3.5E+02 4.0E+02 3.6E+04 8.3E+04 1.5E+03 1.7E+03 2.8E+04
331 NBCI 7.3E+03 1.3E+03 8.0E+02 ND ND ND 8.6E+04 2.6E+05 6.5E+02 6.4E+02 6.2E+04
334 NBCI 3.7E+03 6.1E+02 1.1E+03 2.3E+01 1.9E+01 4.0E+01 7.8E+04 1.4E+05 2.5E+03 1.3E+03 5.1E+04
336 NBCI 3.6E+03 8.4E+02 2.8E+03 4.3E+02 1.2E+02 2.5E+02 8.9E+04 2.1E+05 7.9E+03 3.1E+03 9.5E+04
337 NBCI 5.0E+03 9.3E+02 1.1E+03 1.6E+02 2.5E+02 ND 6.5E+04 1.9E+05 3.3E+03 1.3E+03 4.2E+04
339 NBCI 2.5E+03 3.2E+02 5.2E+02 3.4E+01 4.3E+01 6.3E+01 5.0E+04 8.7E+04 2.3E+03 7.7E+02 3.2E+04
361 NBCI 7.9E+03 2.5E+03 6.7E+02 5.8E+02 1.4E+03 3.5E+02 6.7E+04 2.5E+05 1.5E+03 2.8E+03 4.7E+04
363 NBCI 6.2E+03 1.7E+03 1.4E+03 1.1E+02 1.9E+02 5.2E+01 7.6E+04 1.4E+05 3.7E+03 7.3E+02 7.2E+04
34 BCI 1.9E+03 1.7E+03 5.7E+02 2.4E+02 1.2E+02 3.7E+02 6.7E+04 5.6E+05 6.1E+03 1.5E+03 1.2E+05
71 BCI 7.6E+03 1.2E+03 1.3E+03 1.7E+01 1.8E+02 2.1E+01 9.5E+04 6.7E+05 1.8E+04 2.4E+02 2.2E+05
85 BCI 1.0E+04 9.7E+02 8.7E+02 6.3E+01 ND ND 2.6E+04 4.9E+04 1.1E+03 3.9E+02 2.3E+04
88 BCI 1.5E+03 4.0E+02 4.2E+02 1.1E+02 ND ND 3.1E+04 2.9E+04 2.7E+03 3.6E+02 3.9E+04
99 BCI 1.4E+04 3.3E+03 2.6E+03 2.2E+02 3.1E+03 1.4E+02 2.1E+05 2.0E+05 3.7E+03 9.3E+02 1.4E+05
118 BCI 1.5E+03 1.2E+03 2.8E+02 ND ND 1.4E+02 2.4E+04 3.5E+04 1.9E+03 1.2E+03 1.7E+04
146 BCI 1.9E+04 1.2E+03 2.3E+02 1.2E+02 1.6E+03 6.0E+01 3.1E+04 1.4E+05 4.9E+03 2.7E+02 6.2E+04
147 BCI 2.8E+03 1.3E+03 N/A2 3.6E+02 2.8E+02 3.8E+02 6.1E+04 3.0E+05 2.7E+03 1.1E+03 1.8E+04
158 BCI 4.9E+03 8.8E+02 1.9E+02 2.8E+01 4.0E+02 6.8E+01 2.2E+04 1.4E+05 1.7E+03 1.5E+02 1.3E+04
167 BCI 6.7E+03 9.2E+02 4.2E+02 1.8E+02 8.2E+02 3.8E+02 8.9E+04 1.1E+05 2.2E+03 2.8E+02 4.1E+04
171 BCI 1.0E+04 3.9E+03 3.2E+03 5.1E+02 8.9E+01 2.4E+02 5.3E+05 8.3E+05 1.3E+04 6.3E+02 1.6E+05
191 BCI 1.6E+04 2.4E+03 1.5E+02 1.5E+02 7.1E+01 1.2E+02 2.0E+04 9.6E+04 2.5E+03 3.4E+02 1.2E+04
211 BCI 3.8E+03 1.1E+03 6.5E+02 6.3E+02 3.2E+02 2.9E+02 8.3E+04 3.5E+05 2.8E+03 3.2E+02 9.1E+04
212 BCI 1.8E+04 2.8E+03 6.0E+02 3.4E+02 2.0E+02 2.2E+02 3.4E+04 2.1E+05 5.2E+03 3.0E+02 3.6E+04
247 BCI 6.5E+03 7.5E+02 6.4E+02 1.8E+02 ND 1.2E+02 7.8E+04 4.4E+04 5.5E+02 2.7E+03 1.3E+04
255 BCI 1.9E+04 1.1E+03 6.1E+02 1.8E+01 2.3E+02 7.6E+01 1.1E+05 6.5E+05 1.2E+04 1.2E+03 3.8E+05
259 BCI 8.4E+03 6.4E+02 5.1E+02 ND 6.7E+01 4.0E+01 4.7E+04 1.5E+05 2.6E+03 3.8E+02 7.9E+04
271 BCI 4.1E+03 6.6E+02 1.4E+03 6.5E+01 2.7E+02 1.9E+02 9.1E+04 1.5E+05 1.6E+03 ND 1.5E+05
287 BCI 8.7E+03 1.1E+03 9.5E+01 7.4E+01 4.0E+01 2.6E+02 4.7E+04 1.2E+05 6.5E+03 1.1E+02 4.1E+04
300 BCI 4.9E+03 4.4E+02 4.1E+02 4.4E+01 ND 5.1E+01 3.4E+04 6.9E+04 1.0E+03 1.0E+03 2.6E+04
306 BCI 6.5E+03 6.8E+02 4.9E+02 4.4E+01 ND 1.7E+01 3.7E+04 2.5E+05 2.8E+03 3.2E+02 4.1E+04
314 BCI 4.4E+03 9.3E+02 4.8E+02 3.1E+02 ND 1.9E+02 5.3E+04 6.2E+04 4.5E+03 5.2E+02 3.1E+04
329 BCI 1.4E+04 3.5E+02 2.4E+02 ND ND ND 7.9E+04 1.5E+05 1.4E+03 ND 1.5E+05
335 BCI 4.2E+03 3.7E+02 2.2E+03 3.3E+02 2.4E+02 2.4E+02 4.8E+04 1.9E+05 9.8E+03 3.1E+02 3.3E+04
B3 BCI 7.4E+03 9.3E+02 1.4E+02 2.4E+02 1.8E+02 3.8E+02 3.4E+04 1.6E+05 2.2E+03 2.8E+02 4.1E+04
SUBJECT # GROUP GPX1 GPX3 GSTM15 GSTM3 GSTP1 GSTT1 GSTZ1 MGST1 SOD1 XPA XRCC1
63 NBCI 8.4E+05 1.5E+03 7.3E+03 3.9E+03 1.9E+06 ND 3.1E+03 1.7E+05 1.6E+05 2.5E+03 2.1E+04
64 NBCI 4.4E+05 3.1E+02 1.5E+04 2.6E+03 3.5E+06 6.4E+03 2.0E+03 1.6E+05 6.5E+05 2.2E+03 4.2E+04
136 NBCI 2.0E+05 5.2E+02 6.3E+03 2.2E+03 5.3E+05 ND 8.9E+02 3.2E+04 5.3E+04 1.1E+03 4.4E+03
139 NBCI 1.8E+06 3.2E+03 5.2E+04 8.3E+03 3.2E+07 ND 2.8E+04 8.4E+05 2.2E+06 2.6E+04 1.6E+05
150 NBCI 2.1E+05 2.8E+03 1.1E+04 1.1E+03 1.5E+06 ND 3.1E+03 3.1E+04 2.0E+05 2.0E+03 3.1E+04
156 NBCI 4.8E+05 3.9E+03 1.9E+04 6.5E+03 2.9E+06 ND 4.9E+03 5.8E+04 1.3E+05 4.0E+03 2.5E+04Page 6 of 14
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of E2F1. Neither the internal standard, nor the native
cDNA PCR product was observed. The presence of gene-
specific PCR inhibition was observable in some other
samples as reduction in peak heights in internal standard
PCR products relative to that expected for the number of
internal standard molecules present at the beginning of
the PCR reaction. However, in each such case, the PCR
amplification was efficient enough to enable quantifica-
tion.
Bivariate analysis
In non-BC individuals there was significant (p < 0.01) cor-
relation between CEBPG and eight of the 16 antioxidant
157 NBCI 2.4E+06 2.0E+03 2.6E+04 3.3E+03 1.8E+07 8.5E+03 3.6E+03 3.6E+05 1.8E+06 6.2E+03 1.7E+05
194 NBCI 5.4E+05 4.0E+03 1.2E+04 1.1E+03 7.8E+06 7.7E+03 3.2E+03 9.6E+04 5.8E+05 3.7E+03 2.4E+05
210 NBCI 3.2E+05 3.3E+03 4.1E+03 2.6E+03 3.9E+06 1.8E+03 3.7E+03 7.2E+04 3.3E+05 4.8E+03 2.9E+04
257 NBCI 6.3E+05 2.5E+03 1.1E+04 1.2E+02 2.8E+06 8.7E+03 2.9E+03 2.3E+04 1.2E+05 2.6E+03 4.9E+04
261 NBCI 7.6E+05 4.7E+03 1.6E+04 7.4E+03 3.1E+06 1.5E+03 1.8E+03 1.2E+05 4.5E+05 4.9E+03 7.2E+04
282 NBCI 4.6E+05 2.5E+03 1.3E+04 2.3E+03 1.9E+06 1.5E+04 1.3E+03 6.5E+04 4.5E+05 2.0E+03 3.1E+04
285 NBCI 4.3E+05 5.3E+03 8.4E+04 6.2E+02 3.5E+06 7.3E+03 9.2E+03 3.0E+04 2.3E+05 ND 2.0E+04
296 NBCI 8.1E+05 1.5E+03 7.4E+03 4.1E+03 3.6E+06 8.1E+03 4.5E+03 2.0E+05 5.4E+05 2.6E+03 5.2E+04
305 NBCI 1.4E+05 6.5E+02 4.0E+03 3.2E+03 1.6E+06 ND 6.9E+02 4.1E+04 1.8E+05 1.3E+03 5.7E+03
315 NBCI 4.2E+05 7.6E+03 5.1E+03 3.1E+03 7.9E+06 7.2E+03 4.3E+03 7.3E+04 4.5E+05 1.0E+04 3.8E+04
330 NBCI 1.2E+05 2.0E+03 5.8E+03 3.5E+03 1.1E+06 3.1E+01 1.3E+03 2.9E+04 2.3E+05 1.4E+03 1.7E+04
331 NBCI 6.1E+05 3.4E+03 1.3E+04 3.6E+03 7.3E+06 1.0E+04 1.8E+03 1.2E+05 1.3E+06 1.9E+03 5.7E+04
334 NBCI 6.5E+05 4.0E+03 2.7E+04 1.7E+04 3.7E+06 4.6E+03 3.0E+03 6.8E+04 5.9E+05 2.9E+03 2.6E+04
336 NBCI 4.7E+05 2.7E+03 4.4E+04 1.6E+03 3.4E+06 1.2E+04 8.3E+03 6.2E+04 5.4E+05 4.2E+03 1.2E+05
337 NBCI 2.8E+05 2.8E+03 3.8E+03 4.3E+03 1.5E+06 5.3E+03 5.6E+03 4.9E+04 3.3E+05 1.7E+03 4.4E+04
339 NBCI 3.1E+05 1.6E+04 3.0E+04 1.1E+03 3.5E+06 6.6E+03 2.0E+03 6.6E+04 2.4E+05 2.5E+03 2.2E+04
361 NBCI 3.7E+05 8.4E+02 1.5E+04 1.3E+03 7.8E+06 3.1E+03 2.7E+03 4.8E+04 6.4E+05 6.1E+03 7.7E+04
363 NBCI 6.1E+05 2.7E+03 2.2E+04 2.0E+03 8.1E+06 9.9E+03 2.4E+03 9.7E+04 7.0E+05 7.0E+03 3.6E+04
34 BCI 8.8E+05 3.1E+03 3.4E+03 5.1E+02 1.8E+06 ND 1.9E+03 6.1E+04 2.9E+05 3.1E+03 5.6E+04
71 BCI 8.8E+05 1.3E+04 3.2E+04 2.2E+03 6.7E+06 ND 2.5E+03 4.1E+05 7.5E+05 3.1E+03 5.6E+05
85 BCI 2.3E+05 1.1E+03 2.6E+04 4.1E+03 1.2E+06 1.0E+04 8.1E+02 4.8E+04 1.5E+05 3.5E+03 1.8E+04
88 BCI 1.3E+05 1.5E+03 3.5E+03 1.1E+03 6.9E+05 ND 5.6E+02 2.4E+04 1.9E+05 2.4E+03 1.6E+04
99 BCI 9.0E+05 2.1E+03 1.5E+04 5.5E+03 9.6E+06 6.7E+03 8.0E+03 1.2E+05 9.4E+05 8.5E+03 4.7E+04
118 BCI 8.0E+04 3.8E+03 1.1E+04 4.8E+03 1.7E+06 4.0E+03 4.5E+02 4.4E+04 1.7E+05 1.1E+03 6.1E+03
146 BCI 4.1E+05 2.9E+04 4.7E+04 4.7E+02 2.0E+06 7.1E+03 1.6E+04 6.6E+04 1.7E+05 3.8E+04 6.5E+04
147 BCI 4.1E+05 2.5E+03 8.2E+03 7.3E+02 8.8E+05 1.7E+03 1.3E+03 2.3E+04 6.5E+05 2.3E+02 7.4E+04
158 BCI 2.6E+04 2.6E+03 1.4E+04 4.7E+03 2.3E+06 2.9E+03 1.2E+03 2.3E+04 3.7E+04 1.9E+03 2.3E+04
167 BCI 1.9E+05 2.5E+03 5.3E+03 1.8E+03 2.4E+06 1.4E+04 2.3E+03 9.5E+04 4.0E+05 2.9E+03 2.8E+04
171 BCI 1.6E+06 1.7E+03 1.6E+04 4.0E+03 7.8E+06 6.0E+03 6.5E+03 2.5E+05 1.4E+06 1.4E+04 6.0E+04
191 BCI 4.5E+05 1.9E+03 3.5E+03 2.5E+02 1.7E+06 3.6E+03 5.6E+02 2.1E+04 1.6E+05 2.5E+03 2.1E+04
211 BCI 6.0E+05 1.7E+04 1.1E+04 1.3E+02 1.0E+07 5.5E+03 4.1E+03 2.4E+04 7.1E+05 4.3E+03 8.3E+04
212 BCI 6.5E+04 1.6E+03 9.6E+03 1.1E+03 4.0E+06 8.1E+03 9.5E+02 7.5E+04 9.4E+04 3.1E+03 3.6E+04
247 BCI 2.3E+05 2.0E+02 1.4E+04 2.1E+03 1.3E+06 7.1E+03 1.1E+03 2.4E+04 1.3E+05 1.3E+03 1.1E+04
255 BCI 1.3E+06 7.3E+03 1.5E+04 2.5E+03 2.8E+06 3.8E+04 8.1E+03 1.1E+05 2.8E+06 2.0E+03 1.0E+05
259 BCI 3.0E+06 5.9E+03 1.4E+04 7.0E+03 9.2E+06 5.1E+03 5.1E+03 1.1E+05 5.0E+05 4.8E+03 2.1E+04
271 BCI 7.4E+05 9.5E+02 3.8E+03 2.6E+03 2.4E+06 3.7E+03 3.1E+03 7.1E+04 6.3E+05 4.1E+03 3.0E+04
287 BCI 5.8E+05 8.7E+03 1.1E+04 2.3E+03 1.9E+06 1.5E+04 6.3E+02 8.8E+04 1.2E+05 4.7E+03 3.3E+04
300 BCI 2.7E+05 1.5E+03 7.7E+03 5.0E+03 3.7E+06 7.1E+03 1.9E+03 6.7E+04 3.2E+05 8.0E+02 1.3E+04
306 BCI 4.2E+05 2.0E+02 9.7E+03 2.3E+03 2.2E+06 ND 4.8E+03 5.6E+04 1.1E+06 4.5E+02 1.9E+04
314 BCI 1.6E+05 3.7E+03 1.7E+04 1.1E+03 1.2E+06 1.9E+02 1.5E+03 2.7E+04 2.7E+05 2.8E+03 3.4E+04
329 BCI 2.3E+05 8.9E+03 1.6E+04 5.3E+03 7.2E+06 7.8E+03 1.4E+03 5.7E+04 8.9E+05 1.9E+03 4.8E+04
335 BCI 4.1E+05 6.5E+03 2.1E+04 7.1E+03 4.3E+06 1.8E+02 7.0E+03 6.9E+04 5.2E+05 3.9E+03 4.4E+04
B3 BCI 4.0E+05 3.2E+03 6.0E+03 3.8E+02 1.6E+06 7.7E+03 1.8E+03 1.8E+04 2.6E+05 3.7E+03 1.7E+04
Virtually-multiplexed transcript abundance data for each gene (in the form of molecules/106 β-actin molecules) from all experiments were included 
in the same Standardized Expression Database (SED). These data are now directly comparable to previously published virtually-multiplexed 
transcript abundance data from this laboratory [15], or to Virtually-multiplexed transcript abundance data collected by others who use the NCI-
funded (R24 CA 95806) Standardized Expression Measurement (SEM) Center. The data presented here represent more than 6,000 Virtually-
multiplexed transcript abundance measurements conducted in multiple experiments. The sixteen antioxidant or DNA repair genes and each of the 
six transcription factors except for E2F1 were measured in each NBEC sample from 49 individuals (24 non-BC individuals and 25 BC individuals).
1ND, Not detectable (When 60 molecules of Competitive Template (CT) were added to the reaction, CT was detected but native template was 
not.)
2NA, Not available. E2F1 was measured in all of the samples except for one BC individual (24 non-BC individuals and 24 BC individuals).
Table 3: Virtually-multiplexed transcript abundance data. (Continued)Page 7 of 14
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each transcription factor.
Non-BC Individuals n = 24 BC Individuals n = 25 ALL n = 49
Antioxidant/DNA Repair Genes vs Transcription Factors r Value p Value r Value p Value r Value p Value
CAT vs CEBPB 0.13 1 0.18 1 0.15 1
CAT vs CEBPG 0.65 0.004 0.35 0.48 0.55 <0.0006
CAT vs E2F1* 0.54 0.04 0.68 0.002 0.56 <0.0006
CAT vs E2F3 0.48 0.12 0.18 1 0.37 0.06
CAT vs E2F6 0.26 1 0.3 0.84 0.25 0.48
CAT vs EVI1 -0.01 1 0.21 1 0.08 1
ERCC1 vs CEBPB 0.32 0.78 0.27 1 0.29 0.24
ERCC1 vs CEBPG 0.77 <0.0006 0.42 0.24 0.62 <0.0006
ERCC1 vs E2F1 0.35 0.54 0.39 0.36 0.37 0.06
ERCC1 vs E2F3 0.39 0.36 0.21 1 0.31 0.18
ERCC1 vs E2F6 0.17 1 0.63 0.005 0.42 0.02
ERCC1 vs EVI1 -0.02 1 0.38 0.36 0.17 1
ERCC2 vs CEBPB 0.25 1 0.19 1 0.22 0.84
ERCC2 vs CEBPG 0.63 0.006 0.39 0.3 0.53 <0.0006
ERCC2 vs E2F1 0.39 0.36 0.32 0.72 0.33 0.12
ERCC2 vs E2F3 0.58 0.02 0.22 1 0.42 0.02
ERCC2 vs E2F6 0.37 0.42 0.51 0.06 0.42 0.02
ERCC2 vs EVI1 0.19 1 0.29 0.96 0.23 0.66
ERCC4 vs CEBPB -0.35 0.6 -0.11 1 -0.16 1
ERCC4 vs CEBPG 0.24 1 0.37 0.42 0.25 0.48
ERCC4 vs E2F1 0.42 0.24 0.04 1 0.2 1
ERCC4 vs E2F3 0.6 0.01 0.33 0.6 0.33 0.12
ERCC4 vs E2F6 -0.04 1 0.04 1 0.07 1
ERCC4 vs EVI1 0.24 1 0.33 0.66 0.27 0.36
ERCC5 vs CEBPB 0.4 0.3 0.28 1 0.33 0.12
ERCC5 vs CEBPG 0.79 <0.0006 0.12 1 0.46 0.005
ERCC5 vs E2F1 0.44 0.18 0.45 0.18 0.44 0.01
ERCC5 vs E2F3 0.39 0.36 -0.11 1 0.13 1
ERCC5 vs E2F6 0.41 0.3 0.35 0.54 0.38 0.04
ERCC5 vs EVI1 0.07 1 -0.04 1 0.01 1
GPX1 vs CEBPB 0.49 0.06 0.24 1 0.32 0.12
GPX1 vs CEBPG 0.72 <0.0006 0.19 1 0.4 0.02
GPX1 vs E2F1 0.48 0.12 0.38 0.36 0.43 0.02
GPX1 vs E2F3 0.22 1 -0.004 1 0.08 1
GPX1 vs E2F6 0.06 1 0.36 0.48 0.28 0.3
GPX1 vs EVI1 -0.06 1 0.2 1 0.1 1
GPX3 vs CEBPB -0.18 1 0.14 1 0.02 1
GPX3 vs CEBPG 0.13 1 0.01 1 0.07 1
GPX3 vs E2F1 -0.03 1 -0.17 1 -0.12 1
GPX3 vs E2F3 0.32 0.78 -0.2 1 0.05 1
GPX3 vs E2F6 -0.26 1 0.44 0.18 0.19 1
GPX3 vs EVI1 0.06 1 0.08 1 0.06 1
GSTM1-5 vs CEBPB -0.08 1 0.43 0.18 0.17 1
GSTM1-5 vs CEBPG 0.25 1 0.02 1 0.16 1
GSTM1-5 vs E2F1 0.51 0.06 0.23 1 0.41 0.02
GSTM1-5 vs E2F3 0.29 0.96 -0.16 1 0.1 1
GSTM1-5 vs E2F6 -0.3 0.9 0.006 1 -0.1 1
GSTM1-5 vs EVI1 0.22 1 -0.12 1 0.07 1
GSTM3 vs CEBPB 0.01 1 0.06 1 0.04 1
GSTM3 vs CEBPG -0.007 1 -0.28 1 0.01 1
GSTM3 vs E2F1 0.29 1 0.35 0.54 0.34 0.12
GSTM3 vs E2F3 -0.31 0.84 -0.49 0.06 -0.4 0.03
GSTM3 vs E2F6 -0.11 1 -0.25 1 -0.16 1
GSTM3 vs EVI1 -0.27 1 -0.25 1 -0.25 0.54
GSTP1 vs CEBPB 0.19 1 0.38 0.36 0.28 0.36
GSTP1 vs CEBPG 0.74 <0.0006 0.18 1 0.51 0.001Page 8 of 14
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SOD1, GPX1, ERCC1, CAT and ERCC2 (Table 4). In con-
trast, in BC individuals samples CEBPG was not correlated
with any of the antioxidant or DNA repair genes. These
relationships were not observed with any of the other
transcription factors studied.
For XRCC1, ERCC5, GSTP1, and SOD1 the correlation
with CEBPG was significantly lower in BC individuals
compared to non-BC individuals and the difference was
nearly significant for GPX1 (Fig. 1b). Scatter plots of the
relationship between CEBPG and XRCC1 in non-BC indi-
viduals or BC individuals (Fig. 2a,b) are representative of
the other four genes. Neither CEBPG, nor XRCC1, ERCC5,
GSTP1, SOD1 or GPX1 was significantly correlated with
age, gender, or smoking history in non-BC individuals, BC
individuals, or the combined group.
In non-BC individuals, based on the r2 values from Pear-
son's correlation analysis, CEBPG accounts for much of
the variance in expression of XRCC1 (69%), ERCC5
(62%), GSTP1 (55%), SOD1 (44%), and GPX1 (52%).
E2F1 accounts for some of the remaining variance. For
example, when samples from all 49 non-BC individuals
GSTP1 vs E2F1 0.6 0.01 0.46 0.12 0.56 <0.0006
GSTP1 vs E2F3 0.32 0.78 -0.25 1 0.07 1
GSTP1 vs E2F6 0.1 1 0.35 0.48 0.26 0.42
GSTP1 vs EVI1 0.11 1 0.13 1 0.12 1
GSTT1 vs CEBPB 0.03 1 0.45 0.12 0.24 0.6
GSTT1 vs CEBPG 0.39 0.36 0.16 1 0.3 0.24
GSTT1 vs E2F1 0.07 1 -0.15 1 -0.05 1
GSTT1 vs E2F3 0.35 0.54 -0.1 1 0.17 1
GSTT1 vs E2F6 0.05 1 0.21 1 0.11 1
GSTT1 vs EVI1 -0.26 1 0.22 1 -0.04 1
GSTZ1 vs CEBPB 0.11 1 0.36 0.42 0.25 0.54
GSTZ1 vs CEBPG 0.51 0.06 0.08 1 0.28 0.3
GSTZ1 vs E2F1 0.64 0.004 0.5 0.06 0.58 <0.0006
GSTZ1 vs E2F3 0.42 0.24 0.14 1 0.25 0.54
GSTZ1 vs E2F6 -0.05 1 0.48 0.12 0.32 0.18
GSTZ1 vs EVI1 0.02 1 0.27 1 0.16 1
mGST vs CEBPB 0.31 0.78 0.35 0.48 0.32 0.12
mGST vs CEBPG 0.56 0.02 0.25 1 0.42 0.02
mGST vs E2F1 0.58 0.02 0.54 0.04 0.58 <0.0006
mGST vs E2F3 0.03 1 -0.15 1 -0.06 1
mGST vs E2F6 0.17 1 0.29 0.96 0.27 0.36
mGST vs EVI1 -0.16 1 0.07 1 -0.04 1
SOD1 vs CEBPB 0.13 1 0.15 1 0.14 1
SOD1 vs CEBPG 0.66 0.002 0.009 1 0.36 0.06
SOD1 vs E2F1 0.59 0.02 0.55 0.04 0.56 <0.0006
SOD1 vs E2F3 0.25 1 -0.07 1 0.09 1
SOD1 vs E2F6 0.12 1 0.14 1 0.14 1
SOD1 vs EVI1 -0.17 1 0.03 1 -0.06 1
XPA vs CEBPB 0.31 0.84 0.42 0.24 0.31 0.18
XPA vs CEBPG 0.36 0.54 0.33 0.66 0.34 0.12
XPA vs E2F1 -0.05 1 0.22 1 -0.02 1
XPA vs E2F3 -0.07 1 0.14 1 -0.01 1
XPA vs E2F6 0.55 0.04 0.46 0.12 0.4 0.02
XPA vs EVI1 0.04 1 0.07 1 0.04 1
XRCC1 vs CEBPB 0.36 0.48 0.28 1 0.32 0.18
XRCC1 vs CEBPG 0.83 <0.0006 0.27 1 0.591 <0.0006
XRCC1 vs E2F1 0.32 0.78 0.37 0.48 0.35 0.12
XRCC1 vs E2F3 0.47 0.12 0.22 1 0.35 0.06
XRCC1 vs E2F6 0.26 1 0.54 0.04 0.41 0.02
XRCC1 vs EVI1 -0.009 1 0.12 1 0.06 1
The correlation of logarithmically transformed virtually-multiplexed transcript abundance data (Table 3) from each of the six transcription factors 
with each of the sixteen antioxidant or DNA repair genes was determined. The transformation was necessary due to the wide range of expression 
of each gene among the samples. The correlation coefficient (r value) and level of significance (p value) for each correlation are presented. 
Significance (p < 0.01) was determined using a two-tailed test following Bonferroni adjustment for six multiple comparisons (comparison of each of 
six transcription factors to each of the antioxidant or DNA repair genes).
*values for E2F1 obtained in all but one BC individuals.
Table 4: Bivariate analysis of virtually-multiplexed transcript abundance data values for each antioxidant or DNA repair gene versus 
each transcription factor. (Continued)Page 9 of 14
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was significantly correlated with ERCC5, GSTP1 and
SOD1 (Table 4). Further, in non-BC individuals, E2F1 was
correlated with GSTP1 (Fig. 1c) and the correlation was
lower in BC individuals. However, the difference in corre-
lation between non-BC individuals and BC individuals
was not significant. None of the other transcription fac-
tors were correlated with XRCC1, ERCC5, GSTP1, SOD1,
or GPX1 (Fig. 1a,d,e,f).
Comparison of gene expression with demographic 
characteristics
E2F1 and GSTZ1 each were positively correlated with age.
GSTM1-5 was the only gene with a difference in expres-
Correlation of each transcription factor with XRCC1, ERCC5, GSTP1, SOD1, or GPX1Figure 1
Correlation of each transcription factor with XRCC1, ERCC5, GSTP1, SOD1, or GPX1. (a-f) Each panel presents 
the correlation coefficients (r values) for one transcription factor in relation to each of the five genes: (a) CEBPB, (b) CEBPG, 
(c) E2F1, (d) E2F3, (e) E2F6, (f) EVI1. The p value for each significant correlation is provided above the bar. For CEBPG, pre-
sented in panel b, the difference in r value between non-BC individuals and BC individuals was significant or nearly significant 
for each correlated gene, and the p value for each comparison is provided below the corresponding pair of bars.Page 10 of 14
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sion between former and never smokers.
Discussion
In this study, we tested two hypotheses. First, that there is
inter-individual variation in regulation of key antioxidant
and DNA repair genes by one or more transcription fac-
tors. Second, that individuals with sub-optimal regulation
are selected for development of BC if they smoke ciga-
rettes.
These hypotheses are supported by the findings that a)
there was large inter-individual variation in transcript lev-
els of CEBPG and each of the target genes and in non-BC
individuals, b) CEBPG transcript abundance values were
significantly correlated by bivariate analysis with the tran-
script abundance values of four key antioxidant and DNA
repair genes in non-BC individuals, and c) that there was
no correlation between CEBPG and these genes in BC
individuals.
These results support the hypothesis that each of the anti-
oxidant or DNA repair genes correlated with CEBPG in
non-BC individuals is regulated by CEBPG. This is sup-
ported by the specificity of the CEBPG correlation. That is,
there was lack of correlation between any of the other five
transcription factors assessed and these target genes. Of
particular note is the lack of correlation of the target genes
with CEBPB, which binds to the same recognition site as
CEBPG, and shares its recognition site within each of the
antioxidant or DNA repair genes. However, there are alter-
native explanations for the observed correlation of CEBPG
with antioxidant and DNA repair genes in non-BC indi-
viduals. One possibility is that CEBPG and each of the cor-
related antioxidant or DNA repair genes is regulated by a
transcription factor that is as yet undiscovered, and/or has
a recognition site that is not yet known and was not in the
Genomatix software database.
There also is more than one possible explanation for the
observed lack of correlation between CEBPG and antioxi-
dant or DNA repair genes in BC individuals. For example,
the non-BC individual and BC individual groups are not
perfectly matched with respect to age, gender or smoking
history (Table 1) and each of these factors could contrib-
ute to the observed difference in correlation between
groups. However, the lack of association of transcript
abundance level for CEBPG, XRCC1, ERCC5, GSTP1,
SOD1, or GPX1 with age, gender or smoking history
argues against such an explanation. One way to examine
this possibility is through additional, larger, more closely
matched studies. Another possible explanation is that any
differences in NBEC from BC individuals compared to
non-BC individuals resulted from development of BC,
instead of being a hereditary cause of increased risk for
cancer. The best way to determine this will be to conduct
a prospective study. In such a study, individuals matched
for smoking history will be monitored for development of
BC over time. The correlation of transcript abundance val-
ues for CEBPG relative to transcript abundance values for
Scatter plot representation of bivariate correlation of CEBPG with XRCC1Figure 2
Scatter plot representation of bivariate correlation of CEBPG with XRCC1. (a, b) CEBPG/XRCC1 data from Fig-
ure 1b presented as scatter plots: (a) non-BC individuals, (b) BC individuals.Page 11 of 14
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assessed. It is expected that the greatest incidence of BC
will be among the heaviest smokers. Among the matched
heaviest smokers, it is expected that CEBPG will be signif-
icantly correlated with each of the antioxidant or DNA
repair genes among the non-BC individuals but not corre-
lated in BC individuals.
Thus, there are multiple possible explanations for the
observed findings. However, based on the preponderance
of data thus far available, we conclude that CEBPG is
responsible for optimal transcriptional regulation of key
antioxidant or DNA repair genes in NBEC and that there
is inter-individual variation in the regulation of each of
these genes by CEBPG. If this conclusion is correct, the
individuals at greatest risk for BC will be those with the
most extreme smoking history combined with sub-opti-
mal regulation of the largest number of antioxidant and
DNA repair genes. This, in turn, leads to increased repre-
sentation among BC individuals of individuals with lack
of correlation between CEBPG and each of the affected
antioxidant and/or DNA repair genes.
CEBPG is a truncated CEBP transcription factor [19] and
possesses the sequences necessary for DNA binding and
heterodimer formation, but lacks the sequences necessary
for transactivation [20]. CEBPG forms heterodimers with
other CEBP family members and in other tissues this leads
to increased [21] or decreased [20] transcription of the
regulated gene. CEBPG is known to have stimulatory
effect on the IL-6 and IL-8 promoters in B cell lines [21],
and can also act as a dominant negative regulator of
CEBPA and CEBPB in fibroblast and B cell lines [20].
The data from CEBPG knockout mice support a role for
CEBPG in protecting lungs from oxidant damage. CEBPG-
/- knockout mice are healthy at birth but begin to die
within 24 hours, and histological examination reveals
emphysematous lungs [22]. In humans, risk for emphy-
sema is associated with antioxidant capacity [23], and
there is a strong correlation between risk for emphysema
and risk for BC.
However, it will be important to obtain direct experimen-
tal evidence in NBECs for the role of CEBPG in regulating
the antioxidant and DNA repair genes included in this
study. Correlation between CEBPG and target gene tran-
script levels may not be associated with correlation at the
protein level.
In this study, E2F1 correlation with DNA repair and anti-
oxidant genes was less than the correlation observed with
CEBPG, and the E2F1 correlation was observed in both
non-BC individuals as well as BC individuals. The main-
tained correlation of E2F1 with DNA repair and antioxi-
dant genes in BC individuals suggests that this function is
more tightly controlled in the population and does not
play a role in determination of risk for BC. E2F1 has pre-
viously been reported to regulate transcription of DNA
repair enzyme genes in other cell types, including primary
human fibroblasts and mouse epidermal cells [24,25].
Clearly this would have survival value since DNA repair
gene up-regulation in response to E2F1 provides addi-
tional DNA repair when the DNA is replicating and is par-
ticularly vulnerable to damage.
Epidemiologic assessment of the correlation between a
particular variation in DNA sequence, or polymorphism,
and risk for BC has been a dominant paradigm for many
years. Thus far, these efforts have met with scant success
[26]. A common limitation in design of such studies is
that they involve assessment of a single polymorphism or
occasionally, a few polymorphisms. Further, although the
polymorphism assessed typically resides within a gene
known to protect bronchial epithelium from carcinogens,
oxidants, or DNA damage, the selection of the particular
polymorphism for study is largely empiric, and not based
on known functional properties. These are problems
because multiple infrequent polymorphisms at different
sites may all contribute to risk and unless the key poly-
morphisms can be identified through a functional test, a
statistically valid assessment would require much larger
study populations [27].
The findings of this study support a novel approach to
identifying clinically useful biomarkers. According to the
paradigm used in this study, a) a normal phenotype
results from regulated transcription of a group of genes by
one or more transcription factors, b) the corresponding
risk-conferring or disease phenotype results from sub-
optimal interaction among those same genes, and c) each
phenotype is identifiable and distinguishable through vir-
tually-multiplexed transcript abundance analysis. The
data presented here support the utility of this paradigm in
identifying genes associated with risk for BC.
The next step will be to identify polymorphisms that affect
regulation of XRCC1, ERCC5, GSTP1, SOD1, and GPX1
by CEBPG. Such polymorphisms should yield biomarkers
suitable for more readily accessible samples, such as
peripheral blood or buccal smears. A biomarker combin-
ing polymorphisms that affect regulation with those that
affect function of antioxidant and DNA repair genes is
likely to be the most accurate for identifying individuals at
risk for BC. Biomarkers that accurately identify individu-
als at risk for BC will improve efficacy of chemopreven-
tion and early detection clinical trials.
The observed inter-sample variation in the presence of
gene-specific inhibitors of PCR provides evidence sup-Page 12 of 14
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each quantitative PCR transcript abundance measure-
ment. Including such internal standards in the form of
standardized mixtures of internal standards improves the
reproducibility of transcript abundance measurement and
enables development of a standardized database compris-
ing virtually-multiplexed transcript abundance data. Vir-
tually-multiplexed transcript abundance data are highly
suited to identification of genes that have correlated tran-
script abundance values. Correlation at the transcript
abundance level is an important property of genes that are
co-regulated at the transcription level.
Conclusion
We conclude that in non-BC individuals, CEBPG regulates
transcription of key antioxidant or DNA repair genes in
NBEC and that in smokers who develop BC, CEBPG regu-
lation is sub-optimal for a sufficient number of antioxi-
dant and/or DNA repair genes to cause increased risk.
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